This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan opposes reconsideration in US antitrust case against Sanofi over insulin

( April 21, 2026, 21:00 GMT | Official Statement) -- MLex Summary: Mylan told a US federal judge that Sanofi-Aventis’ request for reconsideration in an antitrust case over an injectable form of a diabetes drug is a thinly veiled rehash of the same arguments already rejected by the court. Mylan said numerous authorities recognize that such disagreement provides no basis for reconsideration, and the court correctly found that Mylan adequately alleged Sanofi unlawfully bundled rebates.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections